EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Glucagon-Like Peptide-1–Based Therapies in Clinical Practice: Key Questions, Controversies, and Evidence-Based Recommendations

Alper Sönmez, Sinem Kıyıcı, Arzu Or Koca, Sema Hepşen, Cem Haymana, Fahri Bayram

Endocrinology Research and Practice · 03.11.2026

DOI: 10.5152/erp.2026.26929 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology Research and Practice, online erschienen am 03.11.2026. Verfasst von Alper Sönmez und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-Like Peptide-1–based therapies, including selective and dual receptor agonists, have transformed cardiometabolic medicine. Robust evidence now supports their use in type 2 diabetes mellitus, obesity, cardiovascular prevention, heart failure with preserved ejection fraction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease. The rapid expansion of indications has also exposed real-world challenges, including a substantial burden of adverse events, emerging long-term safety signals, and inequities in access. This review addresses the key clinical questions encountered when prescribing these agents and provide graded recommendations for specialized and general practice, integrating Turkish national real-world data with international trial evidence. The review covers organ-directed safety and monitoring, namely gastrointestinal adverse events, pancreatic and hepatobiliary safety, body composition including muscle and bone, ophthalmic considerations, and thyroid safety. Further issues such as reproductive health, cancer risk, treatment duration and interruption, perioperative and post-bariatric management, and care in special populations will be covered in the next issue. Landmark randomized controlled trials, meta-analyses, regulatory documents, expert consensus statements, and national registry data published through May 2026 were utilized. Recommendations follow a modified American Association of Clinical Endocrinologists grading framework (grade A to D) with a directional indicator (↑ recommended, ↓ not recommended). Universally accepted safety, ethical, or regulatory practices not amenable to formal grading are designated Good Practice Statements. This review provides 77 recommendations across 20 clinical questions in 5 sections. Each part is numbered independently and can be read on its own. Cite this article as: S.nmez A, Kiyici S, Koca AO, Hepşen S, Haymana C, Bayram F. Glucagon-like peptide-1–based therapies in clinical practice: key questions, controversies, and evidence-based recommendations. Endocrinol Res Pract. Published online November 3, 2026. doi: 10.5152/erp.2026.26929.

Zitieren

APA

Sönmez, A., Kıyıcı, S., Koca, A. O., Hepşen, S., Haymana, C., & Bayram, F. (2026). Glucagon-Like Peptide-1–Based Therapies in Clinical Practice: Key Questions, Controversies, and Evidence-Based Recommendations. Endocrinology Research and Practice. https://doi.org/10.5152/erp.2026.26929

Vancouver

Sönmez A, Kıyıcı S, Koca AO, Hepşen S, Haymana C, Bayram F. Glucagon-Like Peptide-1–Based Therapies in Clinical Practice: Key Questions, Controversies, and Evidence-Based Recommendations. Endocrinology Research and Practice. 2026. doi:10.5152/erp.2026.26929

BibTeX
@article{Snmez2026,
  author = {Sönmez, Alper and Kıyıcı, Sinem and Koca, Arzu Or and Hepşen, Sema and Haymana, Cem and Bayram, Fahri},
  title = {Glucagon-Like Peptide-1–Based Therapies in Clinical Practice: Key Questions, Controversies, and Evidence-Based Recommendations},
  journal = {Endocrinology Research and Practice},
  year = {2026},
  doi = {10.5152/erp.2026.26929}
}
Kostenlos starten →